PYXS
Pyxis Oncology·NASDAQ
--
--(--)
--
--(--)
PYXS fundamentals
During Q4 2025, Pyxis Oncology (PYXS) reported revenue of 11.04M, a YoY change of 0.00%. Net income was -18.11M, a YoY change of 49.10%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q3,2020 | Q4,2020 | Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jul 1, 2020 | Oct 1, 2020 | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Sep 30, 2020 | Dec 31, 2020 | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 16.15M -- | -- -- | 0 -- | -- -- | -- -- | 2.82M -- | 0 -- | 11.04M -- | -- -- |
Sales and Services Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 16.15M -- | 0 -- | 0 -- | 0 -- | 0 -100.00% | 2.82M -- | 0 -- | 8.22M -- | 11.04M -- |
Other Revenue | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 2.82M -- | -- -- |
Cost of Revenue | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | 475.00K -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 2.39M -- | -- -- |
Cost of Goods and Services | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 475.00K -- | 0 -- | 0 -- | 0 -- | 0 -100.00% | 0 -- | 0 -- | 2.39M -- | 2.39M -- |
Gross Profit | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | 0 -- | 15.67M -- | 0 -- | 0 -- | 0 -- | 0 -100.00% | 2.82M -- | 0 -- | 8.65M -- | 11.47M -- |
Operating Expenses | 3.19M -- | 4.58M -- | 35.73M -- | 5.94M -- | 11.62M +264.07% | 16.43M +258.72% | 31.39M -12.15% | 25.73M +333.02% | 28.39M +144.32% | 37.97M +131.18% | 20.95M -33.24% | 18.12M -29.56% | 25.35M -10.70% | 17.77M -53.21% | 21.28M +1.54% | 20.03M +10.55% | 23.75M -6.31% | 40.07M +125.52% | 22.91M +7.70% | 22.57M +12.67% | 23.46M -1.23% | 26.95M -32.75% | 95.89M -- |
Selling, General and Administrative Expenses | 767.00K -- | 1.44M -- | 2.96M -- | 2.74M -- | 3.77M +391.79% | 9.20M +538.89% | 11.32M +283.01% | 8.56M +212.72% | 9.36M +148.12% | 8.12M -11.75% | 9.05M -20.01% | 6.73M -21.34% | 10.67M +13.98% | 6.16M -24.13% | 8.25M -8.90% | 6.08M -9.67% | 6.01M -43.63% | 5.08M -17.52% | 5.87M -28.82% | 5.44M -10.56% | 5.65M -5.99% | 5.23M +3.01% | 22.19M -- |
General and Administrative Expenses | -- -- | 3.85M -- | -- -- | -- -- | -- -- | 18.66M +385.26% | -- -- | -- -- | -- -- | 37.35M +100.14% | -- -- | -- -- | 10.67M -- | 6.16M -83.51% | 8.25M -- | 6.08M -- | 6.01M -43.63% | 5.08M -17.52% | 5.87M -28.82% | 5.44M -10.56% | 5.65M -5.99% | 5.23M +3.01% | 22.19M -- |
Research and Development Expenses | 2.42M -- | 3.14M -- | 32.77M -- | 3.21M -- | 7.85M +223.67% | 7.23M +130.20% | 20.07M -38.76% | 17.17M +435.73% | 19.03M +142.50% | 29.85M +313.15% | 11.90M -40.71% | 11.39M -33.66% | 14.69M -22.84% | 11.61M -61.12% | 13.03M +9.48% | 13.95M +22.49% | 17.74M +20.79% | 14.02M +20.82% | 17.04M +30.82% | 17.13M +22.79% | 17.81M +0.38% | 21.71M +54.81% | 73.70M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 20.96M -- | -- -- | -- -- | -- -- | 0 -100.00% | -- -- |
Operating Income | -3.19M -- | -4.58M -- | -35.73M -- | -5.94M -- | -11.62M -264.07% | -16.43M -258.72% | -31.39M +12.15% | -25.73M -333.02% | -28.39M -144.32% | -37.97M -131.18% | -20.95M +33.24% | -18.12M +29.56% | -25.35M +10.70% | -17.77M +53.21% | -5.61M +73.25% | -20.03M -10.55% | -23.75M +6.31% | -40.07M -125.52% | -22.91M -308.81% | -19.75M +1.41% | -23.46M +1.23% | -18.30M +54.34% | -84.42M -- |
Non-Operating Income (Loss) | 1.00K -- | 0 -- | -1.10M -- | -2.21M -- | -2.55M -255500.00% | -403.00K -- | 9.00K +100.82% | 164.00K +107.44% | 719.00K +128.15% | 1.87M +564.52% | 1.71M +18911.11% | 2.22M +1253.66% | 2.31M +220.58% | 2.17M +15.92% | 2.35M +37.29% | 2.73M +23.02% | 2.55M +10.67% | 2.33M +7.56% | 1.76M -25.24% | 1.68M -38.52% | 1.46M -42.85% | 1.29M -44.64% | 6.18M -- |
Income (Loss) from Affiliates | -- -- | 0 -- | -- -- | -231.00K -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Income (Loss) from Joint ventures | -- -- | 0 -- | -- -- | -- -- | -- -- | -231.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Gain (Loss) on Change in Fair Value | -- -- | 0 -- | -- -- | -- -- | -- -- | -6.23M -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Other Non-Operating Income (Loss) | -- -- | 0 -- | -1.10M -- | -1.98M -- | -2.56M -- | 5.82M -- | 9.00K +100.82% | 164.00K +108.28% | 719.00K +128.09% | -892.00K -115.32% | 1.71M +18911.11% | 2.22M +1253.66% | 2.08M +189.01% | 2.02M +326.12% | 2.09M +21.98% | 2.34M +5.59% | 705.00K -66.07% | 6.82M +238.27% | 1.67M -19.89% | 1.58M -32.59% | 684.00K -2.98% | 3.65M -46.48% | 7.59M -- |
Net Interest Expense | -1.00K -- | 0 -- | -4.00K -- | -6.00K -- | -6.00K -500.00% | -7.00K -- | -- -- | -- -- | -- -- | -2.76M -39385.71% | -- -- | -- -- | -227.00K -- | -153.00K +94.46% | -262.00K -- | -387.00K -- | -1.85M -713.22% | 4.49M +3033.99% | -84.00K +67.94% | -99.00K +74.42% | -774.00K +58.07% | 2.36M -47.43% | 1.40M -- |
Interest Income | 1.00K -- | 0 -- | 4.00K -- | 6.00K -- | 6.00K +500.00% | 7.00K -- | -- -- | -- -- | -- -- | 2.76M +39385.71% | -- -- | -- -- | 227.00K -- | 153.00K -94.46% | 262.00K -- | 387.00K -- | 1.85M +713.22% | -4.49M -3033.99% | 84.00K -67.94% | 99.00K -74.42% | 774.00K -58.07% | -2.36M +47.43% | -1.40M -- |
Pretax Income From Continuing Operations | -3.19M -- | -4.58M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | -16.83M -267.53% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -114.52% | -19.24M +38.68% | -15.90M +37.79% | -23.05M +16.71% | -15.60M +56.80% | -3.26M +83.08% | -17.30M -8.80% | -21.20M +8.01% | -37.73M -141.94% | -21.16M -549.82% | -18.07M -4.45% | -22.00M -3.77% | -17.00M +54.94% | -78.23M -- |
Income Tax Expense | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -2.16M -- | -- -- | 283.00K -- | 0 -- | 1.10M +150.97% | -- -- |
Current Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 87.00K -- | -- -- | -- -- | -- -- | 1.39M +1493.10% | -- -- |
Deferred Income Tax | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -2.25M -- | -- -- | -- -- | -- -- | 0 +100.00% | -- -- |
Net Income | -3.19M -- | -4.58M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | -16.83M -267.53% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -114.52% | -19.24M +38.68% | -15.90M +37.79% | -23.05M +16.71% | -15.60M +56.80% | -3.26M +83.08% | -17.30M -8.80% | -21.20M +8.01% | -35.57M -128.06% | -21.16M -549.82% | -18.35M -6.09% | -22.00M -3.77% | -18.11M +49.10% | -79.62M -- |
Net Income Attributable to Owners of the Company | -3.19M -- | -4.58M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | -16.83M -267.53% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -114.52% | -19.24M +38.68% | -15.90M +37.79% | -23.05M +16.71% | -15.60M +56.80% | -3.26M +83.08% | -17.30M -8.80% | -21.20M +8.01% | -35.57M -128.06% | -21.16M -549.82% | -18.35M -6.09% | -22.00M -3.77% | -18.11M +49.10% | -79.62M -- |
Net Income Attributable to Common Stockholders | -3.19M -- | -4.58M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | -16.83M -267.53% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -114.52% | -19.24M +38.68% | -15.90M +37.79% | -23.05M +16.71% | -15.60M +56.80% | -3.26M +83.08% | -17.30M -8.80% | -21.20M +8.01% | -35.57M -128.06% | -21.16M -549.82% | -18.35M -6.09% | -22.00M -3.77% | -18.11M +49.10% | -79.62M -- |
Other Comprehensive Income | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | -- -- | -- -- | -- -- | 0 -- | 696.00K -- | -781.00K -- | -20.00K -- | 168.00K -- | -123.00K -117.67% | -42.00K +94.62% | 453.00K +2365.00% | -181.00K -207.74% | -121.00K +1.63% | -54.00K -28.57% | 74.00K -83.66% | -16.00K +91.16% | -117.00K -- |
Total Comprehensive Income | -3.19M -- | -4.58M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | -16.83M -267.53% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -114.52% | -18.55M +40.90% | -16.68M +34.74% | -23.07M +16.64% | -15.43M +57.26% | -3.38M +81.78% | -17.34M -3.96% | -20.75M +10.05% | -35.75M -131.72% | -21.28M -529.74% | -18.41M -6.14% | -21.93M -5.68% | -18.12M +49.31% | -79.74M -- |
Total Comprehensive Income Attributable to Owners of the Company | -3.19M -- | 8.25M -- | -36.83M -- | -8.15M -- | -14.18M -344.22% | 59.15M +617.01% | -31.38M +14.79% | -25.56M -213.80% | -27.67M -95.23% | -36.10M -161.04% | -18.55M +40.90% | -16.68M +34.74% | -23.07M +16.64% | -15.43M +57.26% | -3.38M +81.78% | -17.34M -3.96% | -20.75M +10.05% | -35.75M -131.72% | -21.28M -529.74% | -18.41M -6.14% | -21.93M -5.68% | -18.12M +49.31% | -79.74M -- |
Basic EPS | -2.93 -- | -- -- | -27.26 -- | -5.54 -- | -8.96 -205.80% | -0.52 -- | -0.97 +96.44% | -0.79 +85.74% | -0.85 +90.51% | -1.03 -98.08% | -0.54 +44.33% | -0.41 +48.10% | -0.56 +34.12% | -0.35 +66.02% | -0.06 +88.89% | -0.29 +29.27% | -0.35 +37.50% | -0.59 -68.57% | -0.35 -483.33% | -0.3 -3.45% | -0.35 -- | -0.29 +50.85% | -1.29 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.56 -- | -- -- | -0.06 -- | -0.29 -- | -0.35 +37.50% | -- -- | -0.35 -483.33% | -0.3 -3.45% | -0.35 -- | -- -- | -- -- |
Diluted EPS | -2.93 -- | -- -- | -27.26 -- | -5.54 -- | -8.96 -205.80% | -- -- | -0.97 +96.44% | -0.79 +85.74% | -0.85 +90.51% | -- -- | -0.54 +44.33% | -0.41 +48.10% | -0.56 +34.12% | -- -- | -0.06 +88.89% | -0.29 +29.27% | -0.35 +37.50% | -- -- | -0.35 -483.33% | -0.3 -3.45% | -0.35 -- | -- -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.56 -- | -- -- | -0.06 -- | -0.29 -- | -0.35 +37.50% | -- -- | -0.35 -483.33% | -0.3 -3.45% | -0.35 -- | -- -- | -- -- |
You can ask Aime
What is Pyxis Oncology's latest dividend and current dividend yield?Did Pyxis Oncology beat or miss consensus estimates last quarter?What is the market's earnings forecast for Pyxis Oncology next quarter?What does Pyxis Oncology do and what are its main business segments?What factors drove the changes in Pyxis Oncology's revenue and profit?What is Pyxis Oncology's gross profit margin?What were the key takeaways from Pyxis Oncology’s earnings call?What guidance did Pyxis Oncology's management provide for the next earnings period?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
